Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Lisata Therapeutics Inc

LSTA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$1.02

▲ +0.99%

Market Cap $11.02M · Vol 22.61K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.02M

Micro Cap

Div Yield

N/A

EPS Growth

+49.74%

YoY

RSI (14)

47.11

Momentum

Beta

1.06

vs Market

52W High

$5.06

79.84% below

52W Low

$0.97

5.15% above

Volume

22.61K

Avg 18.50K

P/B

1.11

Price-to-book

ROE

N/A

Return on equity

Free Float

79.43%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Lisata Therapeutics Inc (LSTA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LSTA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.42%

-29.17%

-0.97%

-67.31%

YTD

-45.16%

-61.80%

-52.56%

-94.09%

Financials & Valuation

TTM · Annual

Total Revenue	$170.00K
Net Income	$-16,586,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-10,711.18%
Net Profit Margin	-9,756.47%
ROE	N/A
ROA · ROIC	-66.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	95.05
P/B	1.11
P/FCF	N/A
EPS Growth	+49.74%
Outstanding Shares	10.80M

Technical Indicators

50-Day SMA	$1.39
200-Day SMA	$2.99
RSI (14)	47.11
Beta	1.06
52-Week High	$5.06
52-Week Low	$0.97

Volume Today	22.61K
Avg Daily Volume (30D)	18.50K
Relative Volume	1.22x
Volatility (10D)	58.69
Volatility (30D)	79.69
Free Float	79.43%

Analyst Consensus

HOLD

Current Price $1.02

Mean Target $15.00

52W Low$0.97 52W High$5.06

Current

Target

$0.97 $5.06

Current Analyst target

+1,370.59% upside potential · 1 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SBTRW6

ISINUS1280583022

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.